Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
Open accessPublished version of a preprint
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Treatment with combined immune checkpoint blockade (CICB) targeting CTLA-4 and PD-1 is associated with clinical benefit across tumor types, but also a high rate of immune-related adverse events. Insights into biomarkers and mechanisms of response and toxicity to CICB are needed. To address this, we profiled the blood, tumor and gut microbiome of 77 patients with advanced melanoma treated with CICB, with a high rate of any ≥grade 3 immune-related adverse events (49%) with parallel studies in pre-clinical models. Tumor-associated immune and genomic biomarkers of response to CICB were similar to those identified for ICB monotherapy, and toxicity from CICB was associated with a more diverse peripheral T-cell repertoire. Profiling of gut microbiota demonstrated a significantly higher abundance of Bacteroides intestinalis in patients with toxicity, with upregulation of mucosal IL-1β in patient samples of colitis and in pre-clinical models. Together, these data offer potential new therapeutic angles for targeting toxicity to CICB. Clinical benefit or intestinal toxicity resulting from combined immune checkpoint blockade in patients with melanoma associates with prevalent commensal bacteria and can be decoupled by IL-1R inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures












Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Gut bacteria modulate the response to immune checkpoint blockade (ICB) treatment in cancer”
From Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Another study linked toxicity with dual CTLA-4 and PD-1 inhibition to an increased abundance of Bacteroides intestinalis in the stool of patients with melanoma.40”
From Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors (2024) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“This phenomenon is particularly pronounced in dual ICI combination therapies, where it has been associated with an increased incidence of severe AEs30.”
From Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors (2025) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“Despite these findings, some studies have reported conflicting results regarding the direct association between microbiota diversity and ICI efficacy30,143.”
From Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors (2025) · cites this paper as [30]
In the citing paper
“Gut microbes, such as Bacteroides, could also be a biomarker for predicting ICI therapeutic toxicity in advanced melanoma patients treated with combined CTLA-4 and PD-1 blockade [131].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [131]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Million, M., Tidjani Alou, M., Khelaifia, S., Bachar, D., Lagier, J.-C., Dione, N., Brah, S., Hugon, P., Lombard, V., Armougom, F., et al. (2016) · Scientific Reports · doi:10.1038/srep26051 · Cited by 204
Self-citationRetractedAngelakis, E., Bachar, D., Henrissat, B., Armougom, F., Audoly, G., Lagier, J., Robert, C., & Raoult, D. (2016) · Scientific Reports · doi:10.1038/srep26276 · Cited by 83
Self-citationRetractedQIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Search and clustering orders of magnitude faster than BLAST
Edgar, R. C. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq461 · Cited by 20,826
UPARSE: highly accurate OTU sequences from microbial amplicon reads
Edgar, R. C. (2013) · Nature Methods · doi:10.1038/nmeth.2604 · Cited by 16,707
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Structure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
Cited by
Immune-checkpoint inhibitors: long-term implications of toxicity
Johnson, D. B., Nebhan, C. A., Moslehi, J. J., & Balko, J. M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00600-w · Cited by 982
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
Spencer, C. N., McQuade, J. L., Gopalakrishnan, V., McCulloch, J. A., Vetizou, M., Cogdill, A. P., Khan, M. A. W., Zhang, X., White, M. G., Peterson, C. B., et al. (2021) · Science · doi:10.1126/science.aaz7015 · Cited by 966
Self-citationDizman, N., Meza, L., Bergerot, P., Alcantara, M., Dorff, T., Lyou, Y., Frankel, P., Cui, Y., Mira, V., Llamas, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01694-6 · Cited by 515
Targeting the gut and tumor microbiota in cancer
Park, E. M., Chelvanambi, M., Bhutiani, N., Kroemer, G., Zitvogel, L., & Wargo, J. A. (2022) · Nature Medicine · doi:10.1038/s41591-022-01779-2 · Cited by 496
Self-citationGut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies
(2022) · doi:10.1186/s13045-022-01273-9 · Cited by 495
“Gut microbes, such as Bacteroides, could also be a biomarker for predicting ICI therapeutic toxicity in advanced melanoma patients treated with combined CTLA-4 and PD-1 blockade [131].”
Background
Metadata
- Authors
- Andrews, M. C., Duong, C. P. M., Gopalakrishnan, V., Iebba, V., Chen, W.-S., Derosa, L., Khan, M. A. W., Cogdill, A. P., White, M. G., Wong, M. C., Ferrere, G., Fluckiger, A., Roberti, M. P., Opolon, P., Alou, M. T., Yonekura, S., Roh, W., Spencer, C. N., Curbelo, I. F., Vence, L., Reuben, A., Johnson, S., Arora, R., Morad, G., Lastrapes, M., Baruch, E. N., Little, L., Gumbs, C., Cooper, Z. A., Prieto, P. A., Wani, K., Lazar, A. J., Tetzlaff, M. T., Hudgens, C. W., Callahan, M. K., Adamow, M., Postow, M. A., Ariyan, C. E., Gaudreau, P.-O., Nezi, L., Raoult, D., Mihalcioiu, C., Elkrief, A., Pezo, R. C., Haydu, L. E., Simon, J. M., Tawbi, H. A., McQuade, J., Hwu, P., Hwu, W.-J., Amaria, R. N., Burton, E. M., Woodman, S. E., Watowich, S., Diab, A., Patel, S. P., Glitza, I. C., Wong, M. K., Zhao, L., Zhang, J., Ajami, N. J., Petrosino, J., Jenq, R. R., Davies, M. A., Gershenwald, J. E., Futreal, P. A., Sharma, P., Allison, J. P., Routy, B., Zitvogel, L., & Wargo, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Inserm (FR)
- Institut Gustave Roussy (FR)
- Parker Institute for Cancer Immunotherapy (US)
- AstraZeneca (United States) (US)
- University of Rochester Medicine (US)
- Memorial Sloan Kettering Cancer Center (US)
- European Institute of Oncology (IT)
- Aix-Marseille Université (FR)
- McGill University Health Centre (CA)
- Sunnybrook Health Science Centre (CA)
- Baylor College of Medicine (US)
- Corresponding author
- Zitvogel, Laurence
- Wargo, Jennifer A.
- ORCID
- Andrews, Miles C.
- Duong, Connie P. M.
- Gopalakrishnan, Vancheswaran
- Iebba, Valerio
- Chen, Wei-Shen
- Derosa, Lisa
- Khan, Md Abdul Wadud
- Cogdill, Alexandria P.
- White, Michael G.
- Wong, Matthew C.
- Ferrere, Gladys
- Fluckiger, Aurélie
- Roberti, Maria P.
- Opolon, Paule
- Alou, Maryam Tidjani
- Yonekura, Satoru
- Roh, Whijae
- Spencer, Christine N.
- Vence, Luis
- Reuben, Alexandre
- Johnson, Sarah
- Arora, Reetakshi
- Morad, Golnaz
- Lastrapes, Matthew
- Baruch, Erez N.
- Little, Latasha
- Gumbs, Curtis
- Cooper, Zachary A.
- Prieto, Peter A.
- Wani, Khalida
- Lazar, Alexander J.
- Hudgens, Courtney W.
- Callahan, Margaret K.
- Adamow, Matthew
- Postow, Michael A.
- Ariyan, Charlotte E.
- Gaudreau, Pierre-Olivier
- Nezi, Luigi
- Raoult, Didier
- Mihalcioiu, Catalin
- Elkrief, Arielle
- Pezo, Rossanna C.
- Haydu, Lauren E.
- Simon, Julie M.
- Tawbi, Hussein A.
- McQuade, Jennifer
- Hwu, Patrick
- Hwu, Wen-Jen
- Amaria, Rodabe N.
- Burton, Elizabeth M.
- Woodman, Scott E.
- Watowich, Stephanie
- Diab, Adi
- Patel, Sapna P.
- Wong, Michael K.
- Zhao, Li
- Zhang, Jianhua
- Ajami, Nadim J.
- Petrosino, Joseph
- Jenq, Robert R.
- Davies, Michael A.
- Gershenwald, Jeffrey E.
- Futreal, P. Andrew
- Sharma, Padmanee
- Allison, James P.
- Routy, Bertrand
- Zitvogel, Laurence
- Wargo, Jennifer A.
- Venue
- Nature Medicine
- Published
- 2021-07-08
- Volume
- 27
- Issue
- 8
- Pages
- 1432-1441
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC11107795
- OpenAlex
- W3112934313
- Semantic Scholar
- 1e128a098aaec7c7f4085a6e065071c0b46a6710
- Cited by
- 437
- References
- 67
- Citations by year
- 2026: 71 · 2025: 74 · 2024: 77 · 2023: 101 · 2022: 94 · 2021: 19
- FWCI
- 26.77
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- cc-by
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Medicine (publishedVersion)
- Research Square (acceptedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion, cc-by)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Funders
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01CA219896-01A1)
- American Association for Cancer Research (SU2C-AACR-IRG-19-17)
- UT | University of Texas MD Anderson Cancer Center Moonshots Program
- Department of Health | National Health and Medical Research Council (1148680)
- U.S. Department of Health & Human Services | National Institutes of Health (T32CA163185, 1 P50 CA221703-02, 1U54CA224070-03, T32 CA 009599)
- Parcours d’excellence en cancérologie - Fondation Philanthropia
- University of Texas MD Anderson Odyssey Fellowship Program - Kimberley Clark Foundation Award for Scientific Achievement
- Fonds de Recherche du Québec - Santé (32667)
- American Cancer SocietyMelanoma Research AllianceCancer Fighters of Houston
- Ligue Contre le Cancer
- Fondation pour la Recherche Médicale
- Institut National Du Cancer
- Agence Nationale de la Recherche (10-IAHU-03)
- Association pour la recherche sur le cancerFondation Carrefour
- Fulbright France Commission Franco-AmericainéThe John J Kopchick Foundation
- UT | University of Texas MD Anderson Cancer Center (P30 CA016672)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- gut microbiota, immune checkpoint blockade, CTLA-4, PD-1, immune-related adverse events, melanoma, Bacteroides intestinalis, colitis, IL-1β, T cell receptor repertoire, immune-related toxicity
- MeSH terms
- Gastrointestinal Microbiome, Animals, Female, Humans, Melanoma, Mice, Inbred C57BL, Cell Line, Tumor, Mice, Interleukin-1beta, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. https://app.cochat.ai/papers/10.1038/s41591-021-01406-6
- The paper
- Andrews, M. C., Duong, C. P. M., Gopalakrishnan, V., Iebba, V., Chen, W.-S., Derosa, L., Khan, M. A. W., Cogdill, A. P., White, M. G., Wong, M. C., Ferrere, G., Fluckiger, A., Roberti, M. P., Opolon, P., Alou, M. T., Yonekura, S., Roh, W., Spencer, C. N., Curbelo, I. F., . . . Wargo, J. A. (2021). Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nature Medicine. https://doi.org/10.1038/s41591-021-01406-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.